… Board with Leaders in Inherited Retinal Disease and RNATherapy LEIDEN, Netherlands & CAMBRIDGE, Mass., July 21, 2020 … to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today …
Positive preliminary data from InSight extension study of sepofarsen for LCA10 reported – consistent with benefit seen in Phase 1/2 and building confidence in Phase 2/3 Illuminate trial;
Strategic convertible debt financing extends runway into 2023 if fully draw
… to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today … (SAB) with leaders in inherited retinal disease and RNAtherapy. In February, ProQR announced its participation in …
Illuminate Phase 2/3 trial of sepofarsen expected to complete enrollment in Q1 2021; additional data from Phase 1/2 InSight extension study to be reported in H2 2021
Enrollment completed for QR-421a dosing cohorts and data from next Phase 1/2 interim
… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today hosted a … trial and is a first-in-class investigational RNAtherapy designed to address the underlying cause of Leber …
… on track to be reported in H2 2020; Three clinical stage RNA therapies in development for inherited retinal diseases, … trial and is a first-in-class investigational RNAtherapy designed to address the underlying cause of Leber …
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 13, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for
Top-line data from Phase 2/3 pivotal Illuminate trial of sepofarsen for CEP290-mediated LCA10 on track for H1 2022
QR-421a pivotal Sirius and Celeste Phase 2/3 trials in Usher syndrome and retinitis pigmentosa expected to start by yea
… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced the … Sirius and Celeste clinical trials of investigational RNAtherapy QR-421a for people with USH2A mediated retinitis …
… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today reported its … Sepofarsen Sepofarsen (QR-110) is an investigational RNAtherapy designed to restore vision in Leber congenital …